Holen Sie sich die Stockscreener-App
48.85
2.59%
-1.30
Handel nachbörslich:
47.51
-1.34
-2.74%
Schlusskurs vom Vortag:
$50.15
Offen:
$50.26
24-Stunden-Volumen:
717.05K
Relative Volume:
0.76
Marktkapitalisierung:
$2.35B
Einnahmen:
$1.36B
Nettoeinkommen (Verlust:
$123.81M
KGV:
20.27
EPS:
2.41
Netto-Cashflow:
$20.35M
1W Leistung:
-3.25%
1M Leistung:
-8.98%
6M Leistung:
-17.58%
1J Leistung:
-34.39%
1-Tages-Spanne:
$48.17
$50.27
1-Wochen-Bereich:
$48.17
$51.37
52-Wochen-Spanne:
$47.31
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Vergleichen Sie HAE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
48.85 | 2.42B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Dentsply Sirona, Acadia Healthcare, and Haemonetics Stocks Trade Down, What You Need To Know - Yahoo Finance
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025 - Yahoo Finance
Haemonetics (NYSE:HAE) Receives Hold (C-) Rating from Weiss Ratings - MarketBeat
FY2028 EPS Estimates for Haemonetics Cut by Zacks Research - MarketBeat
Q1 EPS Estimates for Haemonetics Cut by Zacks Research - Defense World
Citigroup Lowers Price Target for Haemonetics (HAE) to $64.00 | - GuruFocus
Q1 EPS Estimates for Haemonetics Decreased by Zacks Research - MarketBeat
How Haemonetics Corporation stock responds to bond marketMarket Movement Recap & Low Risk Investment Opportunities - newser.com
Hunter Perkins Capital Management LLC Acquires Shares of 7,100 Haemonetics Corporation $HAE - MarketBeat
Is Haemonetics Corporation HAZ a good long term investmentTechnical Resistance Breaks & High Return Trading Plans - earlytimes.in
What analysts say about Launch Two Acquisition Corp stockEarnings Per Share Trends & Affordable Investment Portfolio - earlytimes.in
Why Haemonetics Corporation (HAZ) stock stays on buy listsJuly 2025 Rallies & Safe Capital Allocation Plans - newser.com
Can trapped investors hope for a rebound in Haemonetics CorporationRate Hike & Growth Oriented Trading Recommendations - newser.com
What the Recent FDA Plasma Guidance Means for Haemonetics Investors in 2025 - simplywall.st
Haemonetics (NYSE:HAE) Reaches New 12-Month LowHere's What Happened - MarketBeat
How to forecast Haemonetics Corporation trends using time seriesTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
Is Haemonetics (HAE) Undervalued? A Fresh Look at the Company’s Current Valuation - simplywall.st
How Haemonetics Corporation (HAZ) stock reacts to weak economyQuarterly Market Review & Daily Profit Maximizing Trade Tips - newser.com
Why analysts recommend Haemonetics Corporation (HAZ) stockJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
Is Haemonetics Corporation (HAZ) stock a buy before earnings resultsMarket Growth Summary & Capital Protection Trading Alerts - newser.com
Published on: 2025-10-01 03:46:03 - newser.com
What technical patterns form on Haemonetics Corporation stock chartsGap Down & Entry and Exit Point Strategies - newser.com
Haemonetics Corporation stock volume spike explained2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Exit strategy if you’re trapped in Haemonetics Corporation2025 Trading Recap & Capital Efficiency Focused Ideas - newser.com
How to use Fibonacci retracement on Haemonetics Corporation2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
Published on: 2025-09-27 20:13:44 - newser.com
Real time breakdown of Haemonetics Corporation stock performanceBuy Signal & Verified Short-Term Plans - newser.com
Published on: 2025-09-26 12:26:45 - newser.com
Will Haemonetics Corporation stock keep outperforming rivalsWeekly Investment Summary & Growth Oriented Trading Recommendations - The British Mountaineering Council
Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know - Yahoo Finance
Haemonetics (NYSE:HAE) Given Outperform Rating at Barrington Research - Defense World
Haemonetics (NYSE:HAE) Earns "Outperform" Rating from Barrington Research - MarketBeat
Haemonetics (HAE) Maintains Rating with Barrington Research | HA - GuruFocus
Voya Investment Management LLC Lowers Holdings in Haemonetics Corporation $HAE - MarketBeat
Is Haemonetics Corporation building a consolidation baseEarnings Recap Report & AI Based Buy and Sell Signals - newser.com
Visual analytics tools that track Haemonetics Corporation performanceJuly 2025 Price Swings & Accurate Intraday Trading Signals - newser.com
Combining machine learning predictions for Haemonetics CorporationM&A Rumor & AI Enhanced Market Trend Forecasts - newser.com
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Harbor Capital Advisors Inc. Lowers Stake in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation’s volatility index tracking explainedDay Trade & Weekly Breakout Watchlists - newser.com
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):